ReviewJournal of perinatology : official journal of the California Perinatal Association2005
Overview of surfactant replacement trials.
Review in Journal of perinatology : official journal of the California Perinatal Association, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Overview of the Effectiveness of Different Surfactant Administration Methods: An Umbrella Review of Meta-Analyses.Pediatric pulmonology · 2026Pooled it
- Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome.The Cochrane database of systematic reviews · 2021Pooled it
- Trial
- The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation.BMC pediatrics · 2014Trial
- Computed tomography assessment of exogenous surfactant-induced lung reaeration in patients with acute lung injury.Critical care (London, England) · 2010Trial
- Article
- Evaluation of a respiratory care protocol including less invasive surfactant administration in preterm infants.Pediatric research · 2024Article
- RDS-NExT workshop: consensus statements for the use of surfactant in preterm neonates with RDS.Journal of perinatology : official journal of the California Perinatal Association · 2023Article
- Prevention of Chronic Morbidities in Extremely Premature Newborns with LISA-nCPAP Respiratory Therapy and Adjuvant Perinatal Strategies.Antioxidants (Basel, Switzerland) · 2023Review
- Should less invasive surfactant administration (LISA) become routine practice in US neonatal units?Pediatric research · 2023Review
- Association of Adherence to Surfactant Best Practice Uses With Clinical Outcomes Among Neonates in Sweden.JAMA network open · 2021Observational
- Predicting Lung Health Trajectories for Survivors of Preterm Birth.Frontiers in pediatrics · 2020Review
- Surfactant Administration in Preterm Infants: Drug Development Opportunities.The Journal of pediatrics · 2019Article
- Observational
- Update of minimally invasive surfactant therapy.Korean journal of pediatrics · 2017Review
- Efficacy of minimally invasive surfactant therapy in moderate and late preterm infants: A multicentre randomized control trial.Paediatrics & child health · 2017Article
- In Reply.Deutsches Arzteblatt international · 2017Article
- Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future.Pediatric research · 2017Review
- hPSC-derived lung and intestinal organoids as models of human fetal tissue.Developmental biology · 2016Review
- Comparison of efficacy and safety of two available natural surfactants in Iran, Curosurf and Survanta in treatment of neonatal respiratory distress syndrome: A randomized clinical trial.Contemporary clinical trials communications · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical trials have evaluated the overall efficacy of surfactant therapy, as well as the relative efficacy of different surfactant preparations, the optimal timing of administration and the optimal dosage. Surfactant therapy leads to significant clinical improvement in infants at risk for, or having, respiratory distress syndrome (RDS). Clinical trials that compared the effects of synthetic or animal-derived surfactant preparations to placebo or no therapy demonstrate that surfactant therapy lead to rapid improvement in oxygenation, decreased ventilator support, decreased risk of pneumothorax, and mortality. Earlier treatment, prophylactic treatment of infants at high risk of developing RDS, and selective re-treatment leads to improved clinical outcome as well. Currently available animal-derived surfactants are superior to non-protein-containing synthetic surfactants. Ongoing evaluation will determine if important differences in animal-derived products are noted. Future trials will evaluate third-generation surfactant products and further refine what constitutes optimal use of surfactant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.